Gene Therapy Zynteglo denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applied a Quantity Limit to Zynteglo — and Why You Can Appeal

Quantity-limit denials for Zynteglo (betibeglogene spartacus) are unusual because it is a one-time gene therapy — there is, by definition, a single administration. When BCBS issues a quantity-limit denial for Zynteglo, it usually means one of the following: the plan's pharmacy benefit system flagged a quantity or administration parameter that does not align with the FDA-approved dosing regimen; a prior administration was recorded in the system and the plan is denying a subsequent request as exceeding the allowed quantity; or a coding or submission error caused the system to apply a standard quantity-limit rule that was not designed for a single-infusion gene therapy.

## Why This Denial Is Appealable

Because Zynteglo is administered as a single treatment course per the FDA-approved prescribing information, any quantity-limit denial that conflicts with the approved dosing regimen lacks a valid clinical or regulatory basis. The appeal should demonstrate that the requested quantity matches the FDA-approved prescribing information exactly, and that the plan's quantity-limit rule — if it exists — is inconsistent with the drug's approved administration parameters.

## Federal Appeal Framework

• Internal appeal (Level 1): File under ACA §2719 / ERISA §503 within the deadline on your denial letter. Quantity-limit appeals based on FDA-label consistency are often resolved at Level 1.
• External review: If the internal appeal fails, request IRO review under ACA §2719. The window is typically 4 months from the final adverse benefit determination — verify the exact date on your denial notice.
• Expedited option: If delay poses a serious health risk, request expedited review for a 72-hour decision.

## Documentation to Gather

1. FDA prescribing label: The full FDA-approved prescribing information for Zynteglo, which specifies the approved administration regimen. Obtain from FDA.gov or the manufacturer. 2. Prescriber administration order: Documentation of the exact administration as ordered by the treating hematologist, confirming it aligns with the FDA-approved prescribing label. 3. Denial letter analysis: A careful review of the denial letter to identify exactly which quantity parameter was flagged — this tells you what the appeal needs to rebut. 4. Prior administration history (if applicable): If a prior administration was recorded, provide documentation clarifying the clinical circumstances and why the current request is appropriate under the prescribing label. 5. Medical-necessity letter: Prescriber's statement confirming the administration is consistent with the FDA-approved regimen and medically necessary.

## Criteria-Mapping Structure

Request BCBS's quantity-limit policy for Zynteglo. Compare it directly to the FDA-approved prescribing label:

| Plan Quantity-Limit Rule | FDA Prescribing Label Standard | Match? | |---|---|---| | [Plan's stated quantity limit] | [FDA-approved administration regimen per label] | [Document alignment or discrepancy] |

If the plan's rule conflicts with the FDA-approved prescribing information, that conflict is the centerpiece of the appeal. Your prescriber's letter should explicitly state that the ordered quantity is consistent with the FDA label and that the plan's limit, as applied, would prevent access to a medically necessary FDA-approved therapy. Consult the FDA-approved prescribing label directly for the precise administration parameters — do not rely on secondary sources.